{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:09:11Z","timestamp":1793502551280,"version":"4.5.0"},"reference-count":66,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chronic lymphocytic leukemia (CLL) is an immunosuppressive disease characterized by increased infectious morbidity and inferior antitumor activity of immunotherapies. Targeted therapy with Bruton's tyrosine kinase inhibitors (BTKis) or the Bcl-2 inhibitor venetoclax has profoundly improved treatment outcomes in CLL. To overcome or prevent drug resistance and extend the duration of response after a time-limited therapy, combination regimens are tested. Anti-CD20 antibodies that recruit cell- and complement-mediated effector functions are commonly used. Epcoritamab (GEN3013), an anti\u2013CD3\u00d7CD20 bispecific antibody that recruits T-cell effector functions, has demonstrated potent clinical activity in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma. Development of CLL therapy is ongoing. To characterize epcoritamab-mediated cytotoxicity against primary CLL cells, peripheral blood mononuclear cells from treatment-naive and BTKi-treated patients, including patients progressing on therapy, were cultured with epcoritamab alone or in combination with venetoclax. Ongoing treatment with BTKi and high effector-to-target ratios were associated with superior in\u00a0vitro cytotoxicity. Cytotoxic activity was independent of CD20 expression on CLL cells and observed in samples from patients whose condition progressed while receiving BTKi. Epcoritamab induced significant T-cell expansion, activation, and differentiation into Th1 and effector memory cells in all patient samples. In patient-derived xenografts, epcoritamab reduced the blood and spleen disease burden compared with that in mice receiving a nontargeting control. In\u00a0vitro, the combination of venetoclax with epcoritamab induced superior killing of CLL cells than either agent alone. These data support the investigation of epcoritamab in combination with BTKis or venetoclax to consolidate responses and target emergent drug-resistant subclones.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022009517","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T15:02:20Z","timestamp":1684854140000},"page":"4089-4101","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":46,"title":["Cytotoxicity of the CD3\u00d7CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting"],"prefix":"10.1182","volume":"7","author":[{"given":"Maissa","family":"Mhibik","sequence":"first","affiliation":[{"name":"1Laboratory of Lymphoid Malignancies, Hematology Branch, The National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4831-3105","authenticated-orcid":false,"given":"Erika M.","family":"Gaglione","sequence":"additional","affiliation":[{"name":"1Laboratory of Lymphoid Malignancies, Hematology Branch, The National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Eik","sequence":"additional","affiliation":[{"name":"1Laboratory of Lymphoid Malignancies, Hematology Branch, The National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Herrick","sequence":"additional","affiliation":[{"name":"1Laboratory of Lymphoid Malignancies, Hematology Branch, The National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Le","sequence":"additional","affiliation":[{"name":"1Laboratory of Lymphoid Malignancies, Hematology Branch, The National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inhye E.","family":"Ahn","sequence":"additional","affiliation":[{"name":"1Laboratory of Lymphoid Malignancies, Hematology Branch, The National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9744-991X","authenticated-orcid":false,"given":"Christopher","family":"Chiu","sequence":"additional","affiliation":[{"name":"2Genmab, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Wielgos-Bonvallet","sequence":"additional","affiliation":[{"name":"2Genmab, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida H.","family":"Hiemstra","sequence":"additional","affiliation":[{"name":"3Genmab, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther C. W.","family":"Breij","sequence":"additional","affiliation":[{"name":"3Genmab, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Chen","sequence":"additional","affiliation":[{"name":"2Genmab, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward B.","family":"Reilly","sequence":"additional","affiliation":[{"name":"4AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearlie K.","family":"Epling-Burnette","sequence":"additional","affiliation":[{"name":"4AbbVie Inc, North Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edith","family":"Szafer-Glusman","sequence":"additional","affiliation":[{"name":"5AbbVie Inc, Sunnyvale, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8498-4729","authenticated-orcid":false,"given":"Clare","family":"Sun","sequence":"additional","affiliation":[{"name":"1Laboratory of Lymphoid Malignancies, Hematology Branch, The National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3533-2924","authenticated-orcid":false,"given":"Adrian","family":"Wiestner","sequence":"additional","affiliation":[{"name":"1Laboratory of Lymphoid Malignancies, Hematology Branch, The National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,7,28]]},"reference":[{"issue":"5","key":"2023080717553776000_bib1","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1056\/NEJMra1908213","article-title":"Treatment of chronic lymphocytic leukemia","volume":"383","author":"Burger","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2023080717553776000_bib2","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.3109\/10428194.2013.777837","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)","volume":"54","author":"Burger","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"2023080717553776000_bib3","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood-2014-02-548610","article-title":"Ibrutinib inhibits BCR and NF-kappaB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL","volume":"123","author":"Herman","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2023080717553776000_bib4","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1038\/s41467-017-02329-y","article-title":"The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy","volume":"8","author":"Landau","year":"2017","journal-title":"Nat Commun"},{"issue":"4","key":"2023080717553776000_bib5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023080717553776000_bib6","first-page":"32","article-title":"Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma","volume":"17","author":"Tam","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"issue":"1","key":"2023080717553776000_bib7","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/hematology.2020000118","article-title":"Managing toxicities of Bruton tyrosine kinase inhibitors","volume":"2020","author":"Lipsky","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"2023080717553776000_bib8","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1182\/blood.2019003715","article-title":"Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib","volume":"136","author":"Sun","year":"2020","journal-title":"Blood"},{"issue":"31","key":"2023080717553776000_bib9","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2023080717553776000_bib10","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"},{"issue":"21","key":"2023080717553776000_bib11","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2017-12-820910","article-title":"Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study","volume":"131","author":"Ahn","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2023080717553776000_bib12","article-title":"ELEVATE TN: phase 3 study of acalabrutinib combined with obinutuzumab (O) or alone Vs O plus chlorambucil (Clb) in patients (Pts) with treatment-naive chronic lymphocytic leukemia (CLL)","volume":"134","author":"Sharman","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2023080717553776000_bib13","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1056\/NEJMc2005943","article-title":"Ibrutinib for chronic lymphocytic leukemia with TP53 alterations","volume":"383","author":"Ahn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023080717553776000_bib14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"11","key":"2023080717553776000_bib15","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2023080717553776000_bib16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2015-02-626846","article-title":"Hypermorphic mutation of phospholipase C, gamma2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation","volume":"126","author":"Liu","year":"2015","journal-title":"Blood"},{"issue":"13","key":"2023080717553776000_bib17","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2023080717553776000_bib18","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2023080717553776000_bib19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/blood.2018882555","article-title":"Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables","volume":"134","author":"Roberts","year":"2019","journal-title":"Blood"},{"issue":"23","key":"2023080717553776000_bib20","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"2023080717553776000_bib21","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1182\/bloodadvances.2021005083","article-title":"Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition","volume":"5","author":"Lew","year":"2021","journal-title":"Blood Adv"},{"issue":"9","key":"2023080717553776000_bib22","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T\u00a0cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"issue":"5","key":"2023080717553776000_bib23","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","article-title":"Perturbation of the normal immune system in patients with CLL","volume":"126","author":"Forconi","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2023080717553776000_bib24","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/1078-0432.CCR-15-1965","article-title":"Disruption of in\u00a0vivo chronic lymphocytic leukemia tumor-microenvironment interactions by ibrutinib - findings from an investigator-initiated phase II study","volume":"22","author":"Niemann","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2023080717553776000_bib25","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J\u00a0Clin Invest"},{"issue":"18","key":"2023080717553776000_bib26","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1158\/1078-0432.CCR-19-3827","article-title":"T-Cell dynamics in chronic lymphocytic leukemia under different treatment modalities","volume":"26","author":"Vardi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2023080717553776000_bib27","doi-asserted-by":"crossref","first-page":"106432","DOI":"10.1016\/j.leukres.2020.106432","article-title":"Ibrutinib restores immune cell numbers and function in first-line and relapsed\/refractory chronic lymphocytic leukemia","volume":"97","author":"Solman","year":"2020","journal-title":"Leuk Res"},{"issue":"1","key":"2023080717553776000_bib28","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40364-020-00253-w","article-title":"Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse","volume":"8","author":"Cadot","year":"2020","journal-title":"Biomark Res"},{"key":"2023080717553776000_bib29","doi-asserted-by":"crossref","first-page":"106520","DOI":"10.1016\/j.leukres.2021.106520","article-title":"Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia","volume":"102","author":"Solman","year":"2021","journal-title":"Leuk Res"},{"issue":"1","key":"2023080717553776000_bib30","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3390\/ijms21010068","article-title":"Harnessing the effects of BTKi on T cells for effective immunotherapy against CLL","volume":"21","author":"Mhibik","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"15","key":"2023080717553776000_bib31","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2023080717553776000_bib32","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/leu.2017.304","article-title":"Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1\/PD-L1 pathway","volume":"32","author":"Kondo","year":"2018","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2023080717553776000_bib33","article-title":"Partial reconstitution of humoral and cellular immunity in patients with chronic lymphocytic leukemia treated with acalabrutinib","volume":"132","author":"Pleyer","year":"2018","journal-title":"Blood"},{"issue":"19","key":"2023080717553776000_bib34","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1182\/blood.2020009686","article-title":"BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19\/CD3-bispecific antibody in CLL","volume":"138","author":"Mhibik","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2023080717553776000_bib35","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood-2018-02-830992","article-title":"A\u00a0CD19\/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era","volume":"132","author":"Robinson","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2023080717553776000_bib36","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1182\/blood-2004-01-0039","article-title":"Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas","volume":"104","author":"Teeling","year":"2004","journal-title":"Blood"},{"key":"2023080717553776000_bib37","doi-asserted-by":"crossref","first-page":"102625","DOI":"10.1016\/j.ebiom.2019.102625","article-title":"DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing","volume":"52","author":"Engelberts","year":"2020","journal-title":"EBioMedicine"},{"issue":"2","key":"2023080717553776000_bib38","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41408-021-00430-6","article-title":"Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment","volume":"11","author":"van der Horst","year":"2021","journal-title":"Blood Cancer J"},{"issue":"10306","key":"2023080717553776000_bib39","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"2023080717553776000_bib40","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 Bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2023080717553776000_bib41","article-title":"Subcutaneous epcoritamab in patients with relapsed\/refractory chronic lymphocytic leukemia: preliminary results from the epcore CLL-1 Trial","volume":"138","author":"Kater","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2023080717553776000_bib42","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/leu.2013.131","article-title":"Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy","volume":"27","author":"Herman","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"2023080717553776000_bib43","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2018-01-785998","article-title":"How and when I do allogeneic transplant in CLL","volume":"132","author":"Gribben","year":"2018","journal-title":"Blood"},{"issue":"25","key":"2023080717553776000_bib44","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1200\/JCO.19.03237","article-title":"Long-term outcomes from a randomized dose optimization study of chimeric antigen receptor modified T cells in relapsed chronic lymphocytic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"2023080717553776000_bib45","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"303","key":"2023080717553776000_bib46","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"issue":"19","key":"2023080717553776000_bib47","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"issue":"21","key":"2023080717553776000_bib48","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1182\/bloodadvances.2022007317","article-title":"Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia","volume":"6","author":"Gill","year":"2022","journal-title":"Blood Adv"},{"key":"2023080717553776000_bib49","doi-asserted-by":"crossref","first-page":"669474","DOI":"10.3389\/fimmu.2021.669474","article-title":"Differentiation and regulation of T(H) cells: a balancing act for cancer immunotherapy","volume":"12","author":"Basu","year":"2021","journal-title":"Front Immunol"},{"issue":"8","key":"2023080717553776000_bib50","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s13238-020-00707-9","article-title":"Memory T cells: strategies for optimizing tumor immunotherapy","volume":"11","author":"Liu","year":"2020","journal-title":"Protein Cell"},{"issue":"17","key":"2023080717553776000_bib51","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.3390\/cancers13174279","article-title":"Clinical and product features associated with outcome of DLBCL patients to CD19-targeted CAR T-cell therapy","volume":"13","author":"Lamure","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"suppl 1","key":"2023080717553776000_bib52","doi-asserted-by":"crossref","first-page":"9283","DOI":"10.1182\/blood-2022-162538","article-title":"Evaluation of epcoritamab and rituximab combination in preclinical models of B-cell non-Hodgkin's lymphoma (NHL)","volume":"140","author":"Epling-Burnette","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2023080717553776000_bib53","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood.V98.12.3383","article-title":"CD20 levels determine the in\u00a0vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59","volume":"98","author":"Golay","year":"2001","journal-title":"Blood"},{"issue":"8","key":"2023080717553776000_bib54","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"issue":"9747","key":"2023080717553776000_bib55","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"2023080717553776000_bib56","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023080717553776000_bib57","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/leu.2014.12","article-title":"B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies","volume":"28","author":"Bojarczuk","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"2023080717553776000_bib58","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3324\/haematol.2014.107011","article-title":"Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy","volume":"100","author":"Da Roit","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"2023080717553776000_bib59","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1158\/1078-0432.CCR-15-1304","article-title":"Interactions between ibrutinib and anti-CD20 antibodies: competing effects on the outcome of combination therapy","volume":"22","author":"Skarzynski","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"10232","key":"2023080717553776000_bib60","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"2023080717553776000_bib61","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1158\/2159-8290.CD-19-1130","article-title":"Acalabrutinib plus obinutuzumab in treatment-naive and relapsed\/refractory chronic lymphocytic leukemia","volume":"10","author":"Woyach","year":"2020","journal-title":"Cancer Discov"},{"issue":"10","key":"2023080717553776000_bib62","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(14)70335-3","article-title":"Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study","volume":"15","author":"Burger","year":"2014","journal-title":"Lancet Oncol"},{"issue":"13","key":"2023080717553776000_bib63","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","author":"Jain","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2023080717553776000_bib64","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.20.00979","article-title":"Prediction of outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: development and validation of a four-factor prognostic model","volume":"39","author":"Ahn","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"2023080717553776000_bib65","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1182\/bloodadvances.2022007034","article-title":"Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4\u00a0T cells","volume":"6","author":"van Bruggen","year":"2022","journal-title":"Blood Adv"},{"issue":"17","key":"2023080717553776000_bib66","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1182\/bloodadvances.2019000360","article-title":"Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment","volume":"3","author":"de Weerdt","year":"2019","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/15\/4089\/2069547\/blooda_adv-2022-009517-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/15\/4089\/2069547\/blooda_adv-2022-009517-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T17:56:13Z","timestamp":1691430973000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/15\/4089\/495983\/Cytotoxicity-of-the-CD3-CD20-bispecific-antibody"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,28]]},"references-count":66,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2023,8,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022009517","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,28]]}}}